Table 1 Baseline patient and disease characteristics in carfilzomib-treated patients reporting a cardiac or vascular-related adverse event
|  | Patients N = 12 |
|---|---|
Age, median years (range) | 59 (49–77) |
Male sex, % | 50 |
Durie-Salmon stage at diagnosis | Â |
IA | 3 |
IIA | 1 |
IIIA | 7 |
IIIB | 1 |
ISS stage at diagnosis | Â |
I | 0 |
II | 3 |
III | 3 |
Unknown | 6 |
Lines of previous anti-MM therapy, median | 5 |
Prior bortezomib, n (%) | 11 (92) |
Prior autologous stem cell transplant, n (%) | 9 (75) |
Prior anthracycline, n (%) | 3 (25) |